PE20160526A1 - Composiciones oftalmologicas no irritantes de povidona-yodo - Google Patents

Composiciones oftalmologicas no irritantes de povidona-yodo

Info

Publication number
PE20160526A1
PE20160526A1 PE2016000435A PE2016000435A PE20160526A1 PE 20160526 A1 PE20160526 A1 PE 20160526A1 PE 2016000435 A PE2016000435 A PE 2016000435A PE 2016000435 A PE2016000435 A PE 2016000435A PE 20160526 A1 PE20160526 A1 PE 20160526A1
Authority
PE
Peru
Prior art keywords
povidone
iodine
agent
lubricant
irritating
Prior art date
Application number
PE2016000435A
Other languages
English (en)
Inventor
Michael Weiser
Jason Stein
Bo Liang
Joseph A Capriotti
C Michael Samson
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160526(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of PE20160526A1 publication Critical patent/PE20160526A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una composicion farmaceutica que comprende: (a) povidona-yodo a una concentracion de 0.1% a 2.5%; (b) un lubricante tal como lagrimas artificiales; (c) un agente refrescante tal como el mentol, sulfonamidas, entre otros; (d) opcionalmente camfor, borneol, un lubricante, un emoliente, un compuesto antiinflamatorio esteroideo tal como dexametasona, medrisona, entre otros, y un compuesto antiinflamatorio no esteroideo tal como ketotifeno, diclofenaco de sodio, entre otros; (e) un agente que incrementa la viscosidad tal como alcohol polivinilico, polivinilpirrolidona, entre otros; (f) un agente bioadhesivo tal como goma de algarrobo, alginato de sodio, entre otros. Dicha composicion es util para aliviar la irritacion ocular moderada, aumentar la comodidad del ojo y para proporcionar un efecto refrescante
PE2016000435A 2009-12-15 2010-12-15 Composiciones oftalmologicas no irritantes de povidona-yodo PE20160526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28669709P 2009-12-15 2009-12-15

Publications (1)

Publication Number Publication Date
PE20160526A1 true PE20160526A1 (es) 2016-05-29

Family

ID=44305700

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000825A PE20121498A1 (es) 2009-12-15 2010-12-15 Composiciones oftalmicas no irritantes de povidona-yodo
PE2016000435A PE20160526A1 (es) 2009-12-15 2010-12-15 Composiciones oftalmologicas no irritantes de povidona-yodo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000825A PE20121498A1 (es) 2009-12-15 2010-12-15 Composiciones oftalmicas no irritantes de povidona-yodo

Country Status (16)

Country Link
US (1) US20130177522A1 (es)
EP (1) EP2512230A4 (es)
JP (3) JP2013514373A (es)
KR (2) KR20120112537A (es)
CN (2) CN104906580A (es)
AR (1) AR079479A1 (es)
AU (1) AU2010339993A1 (es)
BR (1) BR112012014260A2 (es)
CA (1) CA2784492C (es)
CL (1) CL2012001583A1 (es)
EC (1) ECSP12012037A (es)
HK (1) HK1211216A1 (es)
MX (1) MX364441B (es)
PE (2) PE20121498A1 (es)
TW (3) TWI561239B (es)
WO (1) WO2011084473A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
AU2010339993A1 (en) * 2009-12-15 2012-07-26 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
MX360666B (es) * 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
GB201114725D0 (en) * 2011-08-25 2011-10-12 Altacor Ltd Ophthalmic formulations
TW202023575A (zh) * 2011-09-16 2020-07-01 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
CN102429862B (zh) 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
JP6161500B2 (ja) * 2012-10-05 2017-07-12 ロート製薬株式会社 ブロムフェナク含有組成物
JP6304474B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
DK3517100T3 (da) * 2013-02-01 2020-12-14 Allergan Inc Kunstige tårer omfattende natriumhyaluronat og carboxymethylcellulose
WO2014160579A1 (en) * 2013-03-25 2014-10-02 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
US20150064129A1 (en) * 2013-09-04 2015-03-05 Taiwan Biotech Co., Ltd. Wound healing composition
CN103877120B (zh) * 2014-04-02 2017-07-21 程予良 一种膏药
CN107847604B (zh) * 2015-10-25 2020-11-10 艾威药业(珠海)有限公司 眼用原位凝胶处方
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
CN108853074A (zh) * 2017-05-10 2018-11-23 武汉先路医药科技股份有限公司 一种含有溴芬酸钠水合物的药物水性滴眼液及其制备方法
JP2022511335A (ja) * 2018-09-21 2022-01-31 ピー・エス・セラピー・リミテッド 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法
US20240082188A1 (en) * 2021-01-21 2024-03-14 Taejoon Pharmaceutical Co., Ltd. Ophthalmic composition
US20230181625A1 (en) * 2021-12-14 2023-06-15 Harrow Ip, Llc Method and composition for treating infectious conjunctivitis
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU200103B (en) * 1987-04-01 1990-04-28 Biogal Gyogyszergyar Process for producing pharmaceutical compositions for treating lack of epithelium
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
US5126127A (en) * 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
DE9312509U1 (de) * 1993-08-20 1993-10-28 Euro Celtique Sa Präparate zur äußeren Verabreichung von antiseptischen und/oder die Wundheilung fördernden Wirkstoffen
US5849291A (en) * 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
CN1204961A (zh) * 1996-09-26 1999-01-13 老笃制药株式会社 滴眼剂
EP1180017B8 (en) * 1999-05-27 2010-05-19 Euro-Celtique S.A. Preparations with povidon iodine for wound treatment
JP4748289B2 (ja) * 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
JP4355574B2 (ja) * 2001-12-21 2009-11-04 千寿製薬株式会社 点眼剤
ES2212907B1 (es) * 2003-01-20 2005-12-16 Luis Ignacio Olcina Portilla Preparados oftalmologicos a base de povidona yodada.
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
SI1791791T1 (sl) * 2004-09-27 2019-10-30 Special Water Patents B V Postopki in sestavki za obdelavo vode
WO2006039558A2 (en) * 2004-10-09 2006-04-13 Formurex, Inc. Ocular agent delivery systems
CN100335035C (zh) * 2004-10-25 2007-09-05 张帆 一种滴眼剂
JP2006219475A (ja) * 2004-12-28 2006-08-24 Rohto Pharmaceut Co Ltd 眼局所適用製剤
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
JP2007277135A (ja) * 2006-04-05 2007-10-25 Mie Univ 創傷治療用外用剤
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
US20080172032A1 (en) * 2007-01-11 2008-07-17 James Pitzer Gills Method for preventing tissue damage associated with irrigation of tissue with an antimicrobial solution
WO2009097123A1 (en) * 2008-01-28 2009-08-06 Foresight Biotherapeutics, Inc. Device for in-situ generation of povidone-iodine compositions
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
JP2008189677A (ja) * 2008-03-10 2008-08-21 Rohto Pharmaceut Co Ltd 洗浄剤
KR20180014859A (ko) * 2008-06-12 2018-02-09 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 안과 조성물에 대한 신규한 대안적 보존제, 포비돈 요오드
US8753561B2 (en) * 2008-06-20 2014-06-17 Baxter International Inc. Methods for processing substrates comprising metallic nanoparticles
AU2010339993A1 (en) * 2009-12-15 2012-07-26 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
CN102429862B (zh) * 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液

Also Published As

Publication number Publication date
TWI561239B (en) 2016-12-11
TW201717973A (zh) 2017-06-01
AU2010339993A1 (en) 2012-07-26
CN104906580A (zh) 2015-09-16
TWI618539B (zh) 2018-03-21
CN102811610B (zh) 2016-05-18
TWI620569B (zh) 2018-04-11
BR112012014260A2 (pt) 2015-09-15
MX2012006881A (es) 2012-07-04
HK1211216A1 (en) 2016-05-20
JP2018030871A (ja) 2018-03-01
US20130177522A1 (en) 2013-07-11
KR20190049931A (ko) 2019-05-09
CA2784492A1 (en) 2011-07-14
EP2512230A4 (en) 2013-05-22
EP2512230A1 (en) 2012-10-24
TW201630614A (zh) 2016-09-01
AR079479A1 (es) 2012-01-25
JP2013514373A (ja) 2013-04-25
PE20121498A1 (es) 2012-11-30
KR20120112537A (ko) 2012-10-11
JP2016028101A (ja) 2016-02-25
CN102811610A (zh) 2012-12-05
CA2784492C (en) 2020-06-30
CL2012001583A1 (es) 2013-01-11
TW201143783A (en) 2011-12-16
NZ751915A (en) 2020-09-25
ECSP12012037A (es) 2012-08-31
WO2011084473A1 (en) 2011-07-14
MX364441B (es) 2019-04-26

Similar Documents

Publication Publication Date Title
PE20160526A1 (es) Composiciones oftalmologicas no irritantes de povidona-yodo
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP6751016B2 (ja) 眼科用又は耳鼻科用水性組成物
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
AR080368A1 (es) Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oido
PE20141676A1 (es) Composiciones de yodo-povidona estable
AR081553A1 (es) Composicion para el tratamiento de la piel
JP6315755B2 (ja) 異物感緩和点眼剤
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
TW201818922A (zh) 水性液劑
JP2013181020A (ja) 眼科用組成物
AR079696A1 (es) Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular
JP6304475B2 (ja) 点眼剤
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
BR112023006371A2 (pt) Composição oftalmológica tópica
JP2009161456A (ja) 眼科用組成物
PE20090316A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
ES2779525T3 (es) Composición que comprende un éster de alfa-tocoferol para prevención y tratamiento de rinitis alérgica
JP2013133318A (ja) コンタクトレンズ装着液